KalVista Pharmaceuticals (KALV) Current Assets (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Current Assets of $205.9 million in Q3 2025, down 14.81% quarter-over-quarter from $241.7 million in Q2 2025, and up 7.44% year-over-year from $191.6 million in Q3 2024.
KalVista Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $205.9 million for Q3 2025.
- In Q3 2025, Current Assets rose 7.44% year-over-year to $205.9 million; the TTM figure through Jul 2025 stood at $205.9 million (up 7.44% YoY), while the FY2025 annual figure was $241.7 million, up 7.09% from the prior year.
- Current Assets came in at $205.9 million for Q3 2025 at KalVista Pharmaceuticals, down from $241.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $286.0 million in Q4 2024 to a low of $62.5 million in Q1 2021.
- A 5-year average of $189.0 million and a median of $192.1 million in 2023 frame the typical range for Current Assets.
- Across the five-year window, Current Assets surged 243.12% in 2022 and tumbled 45.82% in 2024, its largest moves.
- KalVista Pharmaceuticals' Current Assets stood at $234.5 million in 2021, then tumbled by 35.51% to $151.2 million in 2022, then fell by 14.95% to $128.6 million in 2023, then surged by 122.37% to $286.0 million in 2024, then decreased by 28.0% to $205.9 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $205.9 million, $241.7 million, and $286.0 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 205.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 205.90 Mn |
| Apr 30, 2025 | 241.69 Mn |
| Dec 31, 2024 | 285.98 Mn |
| Oct 31, 2024 | 152.27 Mn |
| Jul 31, 2024 | 191.63 Mn |
| Apr 30, 2024 | 225.69 Mn |
| Jan 31, 2024 | 104.10 Mn |
| Oct 31, 2023 | 128.61 Mn |
| Jul 31, 2023 | 149.84 Mn |
| Apr 30, 2023 | 172.33 Mn |
| Jan 31, 2023 | 192.13 Mn |
| Oct 31, 2022 | 151.22 Mn |
| Jul 31, 2022 | 170.41 Mn |
| Apr 30, 2022 | 193.65 Mn |
| Jan 31, 2022 | 214.46 Mn |
| Oct 31, 2021 | 234.48 Mn |
| Jul 31, 2021 | 249.78 Mn |
| Apr 30, 2021 | 264.26 Mn |
| Jan 31, 2021 | 62.50 Mn |
| Oct 31, 2020 | 72.08 Mn |
| Jul 31, 2020 | 80.23 Mn |
| Apr 30, 2020 | 88.70 Mn |
| Jan 31, 2020 | 99.01 Mn |
| Oct 31, 2019 | 107.89 Mn |
| Jul 31, 2019 | 115.72 Mn |
| Apr 30, 2019 | 115.55 Mn |
| Jan 31, 2019 | 124.06 Mn |
| Oct 31, 2018 | 130.07 Mn |
| Jul 31, 2018 | 55.19 Mn |
| Apr 30, 2018 | 59.38 Mn |
| Jan 31, 2018 | 65.71 Mn |
| Oct 31, 2017 | 34.14 Mn |
| Jul 31, 2017 | 30.19 Mn |
| Apr 30, 2017 | 34.20 Mn |
| Jan 31, 2017 | 37.95 Mn |
| Mar 31, 2016 | 49.47 Mn |
| Dec 31, 2015 | 54.95 Mn |
| Sep 30, 2015 | 61.45 Mn |
| Jun 30, 2015 | 67.00 Mn |
| Mar 31, 2015 | 4.31 Mn |
| Dec 31, 2014 | 4.59 Mn |